Chevy Chase Trust Holdings LLC Lowers Position in Henry Schein, Inc. (NASDAQ:HSIC)

Chevy Chase Trust Holdings LLC lessened its position in Henry Schein, Inc. (NASDAQ:HSIC) by 1.2% in the fourth quarter, HoldingsChannel reports. The firm owned 74,747 shares of the company’s stock after selling 944 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Henry Schein were worth $5,659,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. lifted its stake in shares of Henry Schein by 2.1% in the 3rd quarter. Xponance Inc. now owns 21,839 shares of the company’s stock valued at $1,622,000 after purchasing an additional 443 shares during the period. Everett Harris & Co. CA raised its stake in Henry Schein by 29.1% during the fourth quarter. Everett Harris & Co. CA now owns 104,677 shares of the company’s stock valued at $7,925,000 after buying an additional 23,622 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in Henry Schein during the third quarter valued at $348,000. Caxton Associates LP raised its stake in Henry Schein by 80.8% during the third quarter. Caxton Associates LP now owns 18,991 shares of the company’s stock valued at $1,410,000 after buying an additional 8,486 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Henry Schein by 7.3% during the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock valued at $350,392,000 after buying an additional 322,649 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In related news, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Henry Schein Stock Up 1.0 %

Henry Schein stock opened at $73.17 on Wednesday. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $85.75. The firm has a market cap of $9.40 billion, a price-to-earnings ratio of 23.23, a PEG ratio of 1.80 and a beta of 0.87. The stock has a fifty day simple moving average of $75.05 and a two-hundred day simple moving average of $72.61.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period in the previous year, the firm earned $1.21 EPS. The business’s revenue was down 10.5% on a year-over-year basis. Equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Barrington Research lifted their price objective on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Piper Sandler lifted their price objective on Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. SVB Leerink initiated coverage on Henry Schein in a research note on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective for the company. Evercore ISI lifted their target price on Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. lifted their target price on Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $81.09.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.